Tolebrutinib (1) – Cenrifki®
Secondary progressive multiple sclerosis
Characteristics
| Start date | 01.10.2026 |
|---|---|
| Resolution | 01.04.2027 – active procedure |
| INN | Tolebrutinib |
| Brand name | Cenrifki® |
| Pharm. company | Sanofi-Aventis Deutschland GmbH |
| G-BA Procedure ID | D-1372 |
| Therapeutic area | Nervous system diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions